PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer

BACKGROUND: Neoadjuvant treatment with a dual anti-human epidermal growth factor receptor 2 (HER2) blockade with pyrotinib and trastuzumab has been shown to be effective for HER2-positive breast cancer. METHODS: The genomic characteristics of 425 cancer-related genes from the archived tumour blocks...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Qiyun, Xuhong, Juncheng, Luo, Tao, Ge, Jia, Liu, Feng, Lan, Yang, Chen, Qingqiu, Tang, Peng, Fan, Linjun, Chen, Li, Liang, Yan, Wang, Minghao, Hu, Ying, Zhang, Yi, Bian, Xiuwu, Qi, Xiaowei, Jiang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814131/
https://www.ncbi.nlm.nih.gov/pubmed/36323880
http://dx.doi.org/10.1038/s41416-022-02021-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814131/
https://www.ncbi.nlm.nih.gov/pubmed/36323880
http://dx.doi.org/10.1038/s41416-022-02021-z

Ejemplares similares